About Immudex
Immudex is a company based in Copenhagen (Denmark) founded in 2009.. Immudex has raised $16.35 million across 12 funding rounds. Immudex offers products and services including Dextramer®, Klickmer®, U-Load®, CAR Dextramer®, and Xynapse™-T. Immudex operates in a competitive market with competitors including HYCOR BioMedical, Exagen, Lophius Biosciences, PredictImmune and Kypha, among others.
- Headquarter Copenhagen, Denmark
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Immudex Aps
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$16.35 M (USD)
in 12 rounds
-
Latest Funding Round
$290.6 K (USD), Series A
Feb 10, 2025
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Immudex
Immudex offers a comprehensive portfolio of products and services, including Dextramer®, Klickmer®, U-Load®, CAR Dextramer®, and Xynapse™-T. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Reagents for detecting antigen-specific T cells via flow cytometry.
Tools for T cell activation and expansion in research.
Products for customizable immune monitoring applications.
Reagents for detecting CAR cells in therapies.
System for mimicking TCR immunological synapse.
Unlock access to complete
Unlock access to complete
Funding Insights of Immudex
Immudex has successfully raised a total of $16.35M across 12 strategic funding rounds. The most recent funding activity was a Series A round of $290.6 thousand completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 12
- Last Round Series A — $290,596
-
First Round
First Round
(04 Nov 2009)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2025 | Amount | Series A - Immudex | Valuation |
investors |
|
| Feb, 2024 | Amount | Series A - Immudex | Valuation |
investors |
|
| Mar, 2023 | Amount | Series A - Immudex | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Immudex
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Immudex
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Immudex Comparisons
Competitors of Immudex
Immudex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as HYCOR BioMedical, Exagen, Lophius Biosciences, PredictImmune and Kypha, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of diagnostic instruments and reagents for autoimmune diseases and allergies
|
|
| domain | founded_year | HQ Location |
Diagnostic and monitoring solutions for autoimmune connective diseases are developed.
|
|
| domain | founded_year | HQ Location |
T-cell-based diagnostics for infectious and immune diseases are developed.
|
|
| domain | founded_year | HQ Location |
Tools for diagnosing immune-mediated inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Diagnostic biomarker tests for inflammation and autoimmune diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Immudex
Frequently Asked Questions about Immudex
When was Immudex founded?
Immudex was founded in 2009.
Where is Immudex located?
Immudex is headquartered in Copenhagen, Denmark.
Who is the current CEO of Immudex?
Patrik Dahlen is the current CEO of Immudex.
Is Immudex a funded company?
Immudex is a funded company, having raised a total of $16.35M across 12 funding rounds to date. The company's 1st funding round was a Series A of $245.49K, raised on Nov 04, 2009.
What does Immudex do?
Provider of immune monitoring reagents and services for research and clinical use. It offers a portfolio of products, including dextramer reagents for flow cytometry and other applications, Klickmer reagents, and custom solutions. The products are used to detect and characterize antigen specific immune cells, supporting research in areas such as vaccine development, cell therapy, and infectious disease. It also provides services such as custom allele production and proficiency testing. Its offerings enable researchers and clinicians to gain a deeper understanding of the immune response in various contexts.It provides a range of products and services such as Dextramer and dcode MHC multimers for detailed immune profiling, clinical grade reagents, monomers and U- Load reagents, techincal and scientfic support, and more.
Who are the top competitors of Immudex?
Immudex's top competitors include Exagen, SmartHealth and HYCOR BioMedical.
What products or services does Immudex offer?
Immudex offers Dextramer®, Klickmer®, U-Load®, CAR Dextramer®, and Xynapse™-T.
What is Immudex's valuation?
The valuation of Immudex is $15.11M as of Feb 2025.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.